RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib (RECORD-1)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00410124
First received: December 11, 2006
Last updated: December 7, 2012
Last verified: December 2012
  Purpose

To assess whether daily treatment with RAD001 could slow the growth and spread of metastatic carcinoma of the kidney. The safety of RAD001 was also to be studied in this trial.


Condition Intervention Phase
Metastatic Renal Cell Carcinoma
Drug: RAD001
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Progressive Free Survival (PFS) in Patients Who Receive RAD001 Plus Best Supportive Care(BSC) Versus Patients Who Receive Matching Placebo Plus BSC [ Time Frame: Time from randomization to dates of disease progression, death from any cause or last tumor assessment reported between date of first patient randomized until 28Feb2008 cut of date. ] [ Designated as safety issue: Yes ]
    Progression Free survival is defined as the time from randomization to the date of first documented disease progression or death from any cause. The primary statistical analysis of PFS was based on central radiological assessments using a one-sided stratified log-rank test. Radiological assessments: every 8 weeks (+/-1 week) during the first year and every 12 weeks (+/- 1 week) during the second year and thereafter and at the end of the study. Kaplan-Meier methodology was used to estimate the median PFS for each treatment group.


Secondary Outcome Measures:
  • Overall Survival (OS) Assessed by the Monthly Overall Survival Assessments [ Time Frame: Assessed every month up to 2 years after the last patient was randomized into the study from the date of randomization to the time of death. (Data cutoff was 15Nov2009) ] [ Designated as safety issue: Yes ]
    Overall survival (OS) was defined as the time from date of randomization to date of death due to any cause. Kaplan-Meier methodology was used to estimate the median overall survival for each treatment group

  • Best Overall Response Rate in Patients Who Receive RAD001 Plus BSC Versus Matching Placebo Plus BSC [ Time Frame: Time from randomization to dates of disease progression, death from any cause or last tumor assessment reported, between date of first patient randomized until 28Feb2008 cutoff date ] [ Designated as safety issue: No ]
    The Best Overall Response rate (BOR) is defined as the percentage of patients having achieved confirmed Complete Response + Partial Response. Complete Response (CR) = at least two determinations of CR at least 4 weeks apart before progression. • Partial response (PR) = at least two determinations of PR or better at least 4 weeks apart before progression. Radiological assessments: every 8 weeks (+/-1 week) during the first year and every 12 weeks (+/- 1 week) during the second year and thereafter and at the end of the study.

  • Duration of Response in Patients Who Receive RAD001 Plus BSC Versus Placebo Plus BSC [ Time Frame: Time from randomization to dates of disease progression, death from any cause or last tumor assessment reported, between date of first patient randomized until 28Feb2008 cutoff date ] [ Designated as safety issue: No ]
    Duration of overall response (CR or PR) applies only to patients whose Best Overall Response (BOR) was Complete Response (CR) or Partial Response (PR). The start date is the date of first documented response (CR or PR) and the end date is the date of event defined as the first documented progression or death. Radiological assessments: every 8 weeks (+/-1 week) during the first year and every 12 weeks (+/- 1 week) during the second year and thereafter and at the end of the study.

  • Analysis of Time to Definitive Deterioration of the Global Health Status/QoL Scale(QL) Scores of the EORTC QLQ-30 Questionnaire by at Least 10 Percent Using Kaplan Meier Method, by Treatment. [ Time Frame: Baseline and every 28 days under treatment and at discontinuation from RAD001" until 28Feb2008 cutoff date ] [ Designated as safety issue: No ]
    The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items. Global health status / QoL scale (QL), consisting of 2 questions each scored from 1 (very poor) to 7 (excellent), and with possible scores ranging from 2 to 14. Higher score indicates better functioning. Definitive deterioration by at least 10% is defined as a decrease in score by at least 10% compared to baseline, with no increase above this threshold observed during the course of the study. A single measure reporting a decrease of at least 10% is considered definitive only if it is the last one available for the patient. Time to definitive deterioration is the number of days between the date of randomization and date of assessment at which definitive deterioration is seen.

  • Time to Definitive Deterioration of the FKS-DRS Risk Score by at Least 2 Score Units Using Kaplan-Meier Method, by Treatment. [ Time Frame: Baseline and every 28 days under treatment and at discontinuation from RAD001" until 28Feb2008 cutoff date ] [ Designated as safety issue: No ]
    The Functional Assessment of Cancer Therapy - Kidney Symptom Index, Disease Related Symptoms (FKSI-DRS) is a set of items to assess symptoms experienced by patients with advanced kidney cancer. These symptoms include fatigue, pain, weight loss, dyspnea, cough, fever and hematuria. There were 4 response categories (1=Not at all, 2= A little, 3=Quite a bit, 4=Very much), sum of item responses can range from 0 to 36. "0"= severely symptomatic patient and the highest score is an asymptomatic patient. Definitive deterioration of the FKSI-DRS score was defined as a decrease by at least 2 units compared to baseline, with no later increase above this threshold observed during the study. A single measure reporting a decrease of at least 2 units was considered definitive only if it is the last one available for the patient. Time to definitive deterioration is the number of days between the date of randomization and the date of the assessment at which definitive deterioration is seen.

  • Time to Definitive Deterioration of the Physical Functioning Scale (PF)Score of the EORTC QLQ-C30 Questionnaire by at Least 10 Percent Using Kaplan_Meier Method, by Treatment. [ Time Frame: Baseline and every 28 days under treatment and at discontinuation from RAD001" until 28Feb2008 cutoff date ] [ Designated as safety issue: No ]
    The EORTC QLQ-C30 contains 30 items. These include five functional scales (physical, role, emotional, social and cognitive functioning), three symptom scales fatigue, pain, nausea, and vomiting), a global health status/QoL scale, and six single items (dyspnea, diarrhea, constipation, anorexia, insomnia and financial impact). Physical Functioning (PF) sub-scale, consisting of 5 questions each scored from 1 (not at all) to 4 (very much), and with possible values ranging from 5 to 20. Definitive deterioration by at least 10% is defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the course of the study. A single measure reporting a decrease of at least 10% is considered definitive only if it is the last one available for the patient. Time to definitive deterioration is the number of days between the date of randomization and the date of the assessment at which definitive deterioration is seen.

  • Pharmacokinetics of RAD001:Peak Concentration in a Dosing Interval (C-max); Pre-dose Concentration at 24-h Time Point in Dosing Interval (C-min) and Average Concentration in a Dosing Interval =(C-avg) [ Time Frame: At pre-dose and post-dose: 1 hour, 2 hour, 5 hour, 24 hour of Cycle 1 Day1, Cycle 1 Day 15 and at pre-dose from Cycle 2(day1) and all subsequent treatment cycles up until data cut-off 28 Feb 2008. ] [ Designated as safety issue: No ]
    Blood samples will be collected by direct venipuncture during regularly scheduled visits according to the collection plan provided in the study protocol. C-avg= Area under curve (AUC) in a dosing interval from time-zero to time of the last quantifiable concentration (AUC0-tlast)/ time of the last quantifiable concentration in a dosing interval (tlast)

  • Pharmacokinetics of RAD001: Time at Which C-Max Occurs (t-Max) [ Time Frame: At pre-dose and post-dose: 1 hour, 2 hour, 5 hour, 24 hour of Cycle 1 Day 1, Cycle 1 Day 15 and at pre-dose of From Cycle 2 (Day 1) and all subsequent treatment cycles until data cut-off 28Feb2008. ] [ Designated as safety issue: No ]
    Blood samples will be collected by direct venipuncture during regularly scheduled visits according to the collection plan provided in the study protocol.

  • Pharmacokinetics of RAD001: Area Under Curve (AUC) in a Dosing Interval From Time-zero to Time of the Last Quantifiable Concentration. (AUC 0-tlast) [ Time Frame: At pre-dose and post-dose: 1 hour, 2 hour, 5 hour, 24 hour of Cycle 1 Day 1, Cycle 1 Day 15 and at pre-dose from Cycle 2 (Day 1) and all subsequent treatment cycles until data cut-off 28Feb2008. ] [ Designated as safety issue: No ]
    Blood samples will be collected by direct venipuncture during regularly scheduled visits according to the collection plan provided in the study protocol.

  • Pharmacokinetics of RAD001: Time of the Last Quantifiable Concentration in a Dosing Interval - (Tlast) [ Time Frame: At pre-dose and post-dose: 1 hour, 2 hour, 5 hour, 24 hour of Cycle 1 Day 1, Cycle 1 Day 15 and at pre-dose from Cycle 2 (Day 1) and all subsequent treatment cycles until data cut-off 28Feb2008. ] [ Designated as safety issue: No ]
    Blood samples will be collected by direct venipuncture during regularly scheduled visits according to the collection plan provided in the study protocol.

  • Pharmacokinetics of RAD001: Apparent Systemic Clearance From Blood Following Extravascular Administration (CL/F) [ Time Frame: At pre-dose and post-dose: 1 hour, 2 hour, 5 hour, 24 hour of Cycle 1 Day 1, Cycle 1 Day 15 and at pre-dose from Cycle 2 (Day 1) and all subsequent treatment cycles until data cut-off 28Feb2008. ] [ Designated as safety issue: No ]
    Blood samples will be collected by direct venipuncture during regularly scheduled visits according to the collection plan provided in the study protocol.Apparent oral clearance of RAD001 (CL/F) was calculated using AUC in a dosing interval of 24 hours (AUC0-24hours) value on Day 15 as: CL/F = dose/ AUC0-τ

  • Pharmacokinetics of RAD001: Normalized to Body Surface Area (CL/F) [ Time Frame: At pre-dose and post-dose: 1 hour, 2 hour, 5 hour, 24 hour of Cycle 1 Day 1, Cycle 1 Day 15 and at pre-dose from Cycle 2 (Day 1) and all subsequent treatment cycles until data cut-off 28Feb2008. ] [ Designated as safety issue: No ]
    Blood samples will be collected by direct venipuncture during regularly scheduled visits according to the collection plan provided in the study protocol.


Enrollment: 416
Study Start Date: November 2006
Study Completion Date: October 2011
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RAD001 +BSC
The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
Drug: RAD001
The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
Other Name: Everolimus
Placebo Comparator: Placebo (plus BSC)
Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
Drug: Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with metastatic carcinoma and with histological or cytological confirmation of clear cell RCC (tissue from the original diagnosis of renal cell cancer is acceptable).
  • The date of progression on sunitinib and/or sorafenib must be within 6 months.
  • Patients may have received one or both agents
  • Prior therapy with cytokines (i.e., IL-2, Interferon) and/or VEGF-ligand inhibitors (i.e., bevacizumab) are permitted.
  • Prior vaccine therapy in the adjuvant setting is permitted.
  • Patients with at least one measurable lesion at baseline as per the Response evaluation criteria in solid tumors (RECIST) criteria, either on physical exam or as determined by Computer Tomography (CT) Scan or Magnetic Resonance Imaging (MRI).
  • Patients with a Karnofsky Performance Status ≥70%.
  • Adequate bone marrow, liver and renal function.
  • Patients with a life expectancy ≥ 3 months.
  • Women of childbearing potential must have had a negative serum or urine pregnancy test 48 hours prior to the administration of the first study treatment.
  • Patients who give a written informed consent obtained according to local guidelines

Exclusion Criteria:

  • Patients currently receiving chemotherapy, immunotherapy, or radio-therapy or who have received these within 4 weeks of study entry
  • Patients who have previously received mTOR inhibitors.
  • Patients with a known hypersensitivity to RAD001 or other rapamycins (sirolimus, temsirolimus) or to its excipients.
  • Patients with untreated CNS metastases or who are neurologically unstable despite treatment of the CNS metastases. (Patients with treated CNS metastases, who are neurologically stable off of corticosteroids, are eligible to enter study).
  • Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent
  • Patients with a known history of HIV seropositivity.
  • Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin)
  • Patients who have any severe and/or uncontrolled medical conditions
  • Patients who have a history of another primary malignancy ≤ 3 years, with the exception of non-melanoma skin cancer, and carcinoma in situ of uterine cervix
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes.
  • Patients who are using other investigational agents or who had received investigational drugs ≤ 4 weeks prior to randomization
  • Patients unwilling to or unable to comply with the protocol

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00410124

  Hide Study Locations
Locations
United States, Arkansas
Novartis Investigative Site
Fayetteville, Arkansas, United States, 72703
United States, California
Novartis Investigative Site
Duarte, California, United States, 91010-3000
Novartis Investigative Site
Sacramento, California, United States, 95817
Novartis Investigative Site
San Francisco, California, United States, 94115
Novartis Investigative Site
Santa Monica, California, United States, 90404
United States, Florida
Novartis Investigative Site
Ocoee, Florida, United States, *see dep*
Novartis Investigative Site
Orlando, Florida, United States, 32806
United States, Indiana
Novartis Investigative Site
Indianapolis, Indiana, United States, 46202
Novartis Investigative Site
Indianapolis, Indiana, United States, 46227
United States, Kentucky
Novartis Investigative Site
Louisville, Kentucky, United States, 40202
United States, Maryland
Novartis Investigative Site
Baltimore, Maryland, United States, 21201
United States, Michigan
Novartis Investigative Site
Detroit, Michigan, United States, 48201
United States, Minnesota
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Novartis Investigative Site
Columbia, Missouri, United States, 65201
Novartis Investigative Site
St. Louis, Missouri, United States, 63110
United States, Nevada
Novartis Investigative Site
Las Vegas, Nevada, United States, 89135
United States, New York
Novartis Investigative Site
Buffalo, New York, United States, 14263
Novartis Investigative Site
New York, New York, United States, 10021
United States, North Carolina
Novartis Investigative Site
Chapel Hill, North Carolina, United States, 27599
Novartis Investigative Site
Durham, North Carolina, United States, 27710
Novartis Investigative Site
Raleigh, North Carolina, United States, 27609
United States, Ohio
Novartis Investigative Site
Canton, Ohio, United States, 44718
United States, Oregon
Novartis Investigative Site
Portland, Oregon, United States, 97210
United States, Pennsylvania
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15232
United States, Texas
Novartis Investigative Site
Bedford, Texas, United States, 76022
Novartis Investigative Site
Dallas, Texas, United States, 75246
Novartis Investigative Site
San Antonio, Texas, United States, 78229
Novartis Investigative Site
Tyler, Texas, United States, 75702
United States, Washington
Novartis Investigative Site
Seattle, Washington, United States, 98109-1023
Novartis Investigative Site
Spokane, Washington, United States, 99202
United States, West Virginia
Novartis Investigative Site
Morgantown, West Virginia, United States, 26506
Australia, New South Wales
Novartis Investigative Site
Camperdown, New South Wales, Australia, 2050
Novartis Investigative Site
Randwick, New South Wales, Australia, 2031
Novartis Investigative Site
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Novartis Investigative Site
South Brisbane, Queensland, Australia, 4101
Australia, South Australia
Novartis Investigative Site
Woodville, South Australia, Australia, 5011
Australia, Victoria
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Canada, Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2
Novartis Investigative Site
Vancouver, Alberta, Canada, V5Z 4E6
Canada, Ontario
Novartis Investigative Site
Hamilton, Ontario, Canada, L8V 5C2
Novartis Investigative Site
London, Ontario, Canada, N6A 4G5
Novartis Investigative Site
Toronto, Ontario, Canada, M4N 3M5
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H3G 1A4
France
Novartis Investigative Site
Bordeaux Cedex, France, 33075
Novartis Investigative Site
Lille Cedex, France, 59020
Novartis Investigative Site
Lyon Cedex, France, 69373
Novartis Investigative Site
Paris, France, 75015
Novartis Investigative Site
Saint-Herblain Cédex, France, 44805
Novartis Investigative Site
Strasbourg, France, 67091
Novartis Investigative Site
Toulouse Cedex 3, France, 31052
Novartis Investigative Site
Villejuif Cedex, France, 94805
Germany
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Frankfurt/M, Germany, 60590
Novartis Investigative Site
Hannover, Germany, 30625
Novartis Investigative Site
Kassel, Germany, 34125
Novartis Investigative Site
Mainz, Germany, 55101
Novartis Investigative Site
München, Germany, 81675
Italy
Novartis Investigative Site
Cremona, CR, Italy, 26100
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Modena, MO, Italy, 41100
Novartis Investigative Site
Perugia, PG, Italy, 06129
Novartis Investigative Site
Pavia, PV, Italy, 27100
Novartis Investigative Site
Roma, RM, Italy, 00152
Novartis Investigative Site
Napoli, Italy, 80132
Japan
Novartis Investigative Site
Matsuyama, Ehime, Japan, 791-0280
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 060-8543
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 060-8648
Novartis Investigative Site
Tsukuba, Ibaraki, Japan, 305-8576
Novartis Investigative Site
Kurashiki, Okayama, Japan, 710-8602
Novartis Investigative Site
OsakaSayama, Osaka, Japan, 589-8511
Novartis Investigative Site
Sunto-gun, Shizuoka, Japan, 411-8777
Novartis Investigative Site
Utsunomiya, Tochigi, Japan, 320-0834
Novartis Investigative Site
Chuo-ku, Tokyo, Japan, 104-0045
Novartis Investigative Site
Akita, Japan, 010-8543
Novartis Investigative Site
Chiba, Japan, 260-8717
Novartis Investigative Site
Fukuoka, Japan, 812-8582
Novartis Investigative Site
Osaka, Japan, 537-8511
Novartis Investigative Site
Tokushima, Japan, 770-8503
Netherlands
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Leiden, Netherlands, 2300 RC
Novartis Investigative Site
Nijmegen, Netherlands, 6525 GA
Novartis Investigative Site
Utrecht, Netherlands, 3584CX
Poland
Novartis Investigative Site
Gdañsk, Poland, 80-219
Novartis Investigative Site
Lodz, Poland, 90-153
Novartis Investigative Site
Warszawa, Poland, 00-909
Novartis Investigative Site
Wroclaw, Poland, 50-367
Spain
Novartis Investigative Site
Hospitalet de LLobregat, Barcelona, Spain, 08907
Novartis Investigative Site
Barcelona, Spain, 08035
Novartis Investigative Site
Barcelona, Spain, 08025
Novartis Investigative Site
Madrid, Spain, 28041
Novartis Investigative Site
Valencia, Spain, 46009
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT00410124     History of Changes
Other Study ID Numbers: CRAD001C2240, 2006-002070-21
Study First Received: December 11, 2006
Results First Received: October 23, 2012
Last Updated: December 7, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
advanced kidney cancer
everolimus
kidney cancer
oral therapy

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Adenocarcinoma
Kidney Diseases
Kidney Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Everolimus
Sirolimus
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014